Quick Answer
CRISPR Therapeutics AG reported Total Assets of $2.27 billion for fiscal year 2025.
CRISPR Therapeutics AG Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $2.27B | +1.0% |
| 2024 | $2.24B | +0.6% |
| 2023 | $2.23B | -0.6% |
| 2022 | $2.24B | -18.5% |
| 2021 | $2.75B | +50.5% |
| 2020 | $1.83B | +71.4% |
| 2019 | $1.07B | +118.1% |
| 2018 | $489.02M | +80.2% |
| 2017 | $271.35M | -21.3% |
| 2016 | $344.96M | +116.4% |
| 2015 | $159.42M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.25B | -0.5% | +10.6% |
| June 30, 2025 | $2.03B | -13.3% | -6.3% |
| March 31, 2025 | $2.17B | -11.2% | -3.4% |
| December 31, 2024 | $2.24B | +0.6% | -0.6% |
| September 30, 2024 | $2.26B | +8.1% | -3.6% |
| June 30, 2024 | $2.34B | +6.5% | -4.1% |
| March 31, 2024 | $2.44B | +8.7% | +9.4% |
| December 31, 2023 | $2.23B | -0.6% | +6.8% |
- CRISPR Therapeutics AG showed an increase of +1.0% in Total Assets compared to the prior fiscal year.
- Over the 2015–2025 period, CRISPR Therapeutics AG’s total assets has grown by 1320.9% (from $159.42 million to $2.27 billion).
- The most recent figure is from CRISPR Therapeutics AG’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: